“Amphenmulin’s Promising Antibacterial Activity Against Mycoplasma gallisepticum: A Pharmacokinetic/Pharmacodynamic Study”

https://pubmed.ncbi.nlm.nih.gov/38112481

A new pleuromutilin derivative, amphenmulin, shows promising antibacterial activity against Mycoplasma gallisepticum, as detailed in a pharmacokinetic/pharmacodynamic study, supporting its potential for clinical development.